company background image
CYTK

Cytokinetics NasdaqGS:CYTK Stock Report

Last Price

US$40.49

Market Cap

US$3.8b

7D

-0.5%

1Y

14.1%

Updated

03 Dec, 2022

Data

Company Financials +
CYTK fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

CYTK Stock Overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.

Cytokinetics, Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cytokinetics
Historical stock prices
Current Share PriceUS$40.49
52 Week HighUS$55.80
52 Week LowUS$29.26
Beta0.98
1 Month Change1.86%
3 Month Change-25.10%
1 Year Change14.06%
3 Year Change329.83%
5 Year Change406.13%
Change since IPO-58.09%

Recent News & Updates

Recent updates

Cytokinetics (NASDAQ:CYTK) Has Debt But No Earnings; Should You Worry?

Aug 23
Cytokinetics (NASDAQ:CYTK) Has Debt But No Earnings; Should You Worry?

What You Need To Know About The Cytokinetics, Incorporated (NASDAQ:CYTK) Analyst Downgrade Today

May 09
What You Need To Know About The Cytokinetics, Incorporated (NASDAQ:CYTK) Analyst Downgrade Today

Is Cytokinetics (NASDAQ:CYTK) Using Debt Sensibly?

Apr 25
Is Cytokinetics (NASDAQ:CYTK) Using Debt Sensibly?

Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Just Cut Their EPS Forecasts Substantially

Mar 03
Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Just Cut Their EPS Forecasts Substantially

Broker Revenue Forecasts For Cytokinetics, Incorporated (NASDAQ:CYTK) Are Surging Higher

Jan 09
Broker Revenue Forecasts For Cytokinetics, Incorporated (NASDAQ:CYTK) Are Surging Higher

Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Dec 07
Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Is Cytokinetics (NASDAQ:CYTK) A Risky Investment?

Jul 02
Is Cytokinetics (NASDAQ:CYTK) A Risky Investment?

Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Just Trimmed Their Revenue Forecasts By 10%

May 11
Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Just Trimmed Their Revenue Forecasts By 10%

Shareholder Returns

CYTKUS BiotechsUS Market
7D-0.5%4.2%1.5%
1Y14.1%-7.4%-14.9%

Return vs Industry: CYTK exceeded the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: CYTK exceeded the US Market which returned -14.9% over the past year.

Price Volatility

Is CYTK's price volatile compared to industry and market?
CYTK volatility
CYTK Average Weekly Movement6.7%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: CYTK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CYTK's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997253Robert Blumhttps://www.cytokinetics.com

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy.

Cytokinetics, Incorporated Fundamentals Summary

How do Cytokinetics's earnings and revenue compare to its market cap?
CYTK fundamental statistics
Market CapUS$3.83b
Earnings (TTM)-US$282.14m
Revenue (TTM)US$148.23m

25.8x

P/S Ratio

-13.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYTK income statement (TTM)
RevenueUS$148.23m
Cost of RevenueUS$209.29m
Gross Profit-US$61.06m
Other ExpensesUS$221.08m
Earnings-US$282.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.98
Gross Margin-41.19%
Net Profit Margin-190.34%
Debt/Equity Ratio-3,808.8%

How did CYTK perform over the long term?

See historical performance and comparison